You are here

Article info

Article menu
Download PDFPDF
Case Reports: Findings that shed new light on the possible pathogenesis of a disease
Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis

Authors

  • Reuben Malloy Gastroenterology Department, Mater Hospital Brisbane, Brisbane, Queensland, AustraliaFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia PubMed articlesGoogle scholar articles
  • Richard Fernandes Gastroenterology Department, Mater Hospital Brisbane, Brisbane, Queensland, AustraliaFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia PubMed articlesGoogle scholar articles
  • Jakob Begun Gastroenterology Department, Mater Hospital Brisbane, Brisbane, Queensland, AustraliaFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia PubMed articlesGoogle scholar articles
  • Yoon-Kyo An Gastroenterology Department, Mater Hospital Brisbane, Brisbane, Queensland, AustraliaFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Reuben Malloy; reuben_malloy{at}hotmail.com
View Full Text

Citation

Malloy R, Fernandes R, Begun J, et al
Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis
BMJ Case Reports CP 2022;15:e252140.

Publication history

  • Accepted November 26, 2022
  • First published December 14, 2022.
Online issue publication 
December 14, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.